Reimagining Medicine for Patients with MDS & AML:
Exploring Immuno-oncology and Targeted Therapies
Exploring Immuno-oncology and Targeted Therapies
Click to explore
MOA Resources
Novartis Clinical Trials
-
MDS & AML Mechanism of Action Resources
Graphic Science Series TIM-3 Illustrated: Targeting Immune and Myeloid Cells In MDS & AML
Learn more about Novartis research targeting TIM-3 with the investigational drug sabatolimab in MDS & AML.
Sabatolimab Mechanism of Action
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
-
Featured Clinical Trials & Investigational Compounds
Clinical TrialsMidostaurin + Chemotherapy in FLT3-Mutated AML
Spartalizumab and/or Sabatolimab ± Decitabine/Azacitidine in Patients With AML or MDS
Sabatolimab + Decitabine/Azacitidine in Patients With HR- or VHR-MDS (STIMULUS-MDS1)
Sabatolimab + Azacitidine in Patients With IR-, HR-, or VHR-MDS or CMML-2 (STIMULUS-MDS2)Sabatolimab + Azacitidine and Venetoclax in Patients With AMLCompound CardsSpartalizumab (PDR001)Sabatolimab (MBG453)All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
